Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948116 | 1.00 | GPR35 (0.35) | GPR35ACSS2NR1H4EIF4EBP1PARP1 | |
| SCHEMBL23529314 | 0.92 | GPR35 (0.36) | GPR35ACSS2PARP1PKN1PKN2 | |
| SCHEMBL29948208 | 0.92 | GPR35 (0.36) | GPR35ACSS2PARP1PKN1PKN2 | |
| SCHEMBL24801692 | 0.92 | GPR35 (0.31) | GPR35ACSS2NR1H4 | |
| SCHEMBL23552513 | 0.91 | GPR35 (0.31) | GPR35ACSS2 | |
| SCHEMBL23529398 | 0.90 | PTGER4 (0.38) | NR1H4 | |
| SCHEMBL29948221 | 0.88 | ACSS2 (0.39) | ACSS2PARP1PKN1PKN2 | |
| SCHEMBL23529304 | 0.88 | ACSS2 (0.39) | ACSS2PARP1PKN1PKN2 | |
| SCHEMBL23529335 | 0.87 | XDH (0.39) | GPR35NR1H4 | |
| SCHEMBL23529388 | 0.87 | IDO1 (0.39) | GPR35NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | claimed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | claimed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | claimed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | claimed |
| CN-114981265-A | Compound (I) | CTXT私人有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| CN-114981265-A | Compound (I) | CTXT私人有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | GPR35 1670/4885ACSS2 2077/4885NR1H4 1529/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | GPR35 1499/4885ACSS2 2968/4885NR1H4 848/4885 |
| US-20230062932-A1 | COMPOUNDS | STING1, IRF3, MAVS | GPR35 1562/4885ACSS2 1883/4885NR1H4 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.